Literature DB >> 17916064

Prevalence and predictors of cardiac hypertrophy and dysfunction in patients with Type 2 diabetes.

Piyush M Srivastava1, Paul Calafiore, Richard J Macisaac, Sheila K Patel, Merlin C Thomas, George Jerums, Louise M Burrell.   

Abstract

The aim of the present study was to determine the prevalence and predictors of an abnormal echocardiogram in patients with Type 2 diabetes. Cardiac function and structure were rigorously assessed by comprehensive transthoracic echocardiographic techniques in 229 patients with Type 2 diabetes. Cardiovascular risk factors and diabetic complications were assessed, and predictors of an abnormal echocardiogram were identified using multivariate logistic regression analysis. An abnormal echocardiogram was present in 166 patients (72%). LVH (left ventricular hypertrophy) occurred in 116 patients (51%), and cardiac dysfunction was found in 146 patients (64%), of whom 109 had diastolic dysfunction alone and 37 had systolic+/-diastolic dysfunction. Independent predictors of an abnormal echocardiogram were obesity, age, the number of antihypertensive drugs used (all P<0.001) and creatinine clearance (P<0.05). The risk of an abnormal echocardiogram increased by 9% for each year over 50 years of age {OR (odds ratio), 1.09 [95% CI (confidence interval), 1.04-1.15]}, 3-fold if obesity was present [BMI (body mass index) >30; OR, 4.2 (95% CI, 1.9-9.0)] and by 80% for each antihypertensive agent used [OR, 1.8 (95% CI, 1.3-2.4) per agent]. In conclusion, an abnormal cardiac echocardiogram is common in patients with Type 2 diabetes. Importantly, although cardiac abnormalities can be predicted by traditional risk factors, such as age, obesity and renal function, the absence of micro- or macro-vascular complications does not predict a normal echocardiogram. We suggest that an echocardiogram identifies those with Type 2 diabetes at increased cardiovascular risk due to occult LVH and diastolic dysfunction, and this information may lead to more aggressive management of known risk factors in the clinic.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 17916064     DOI: 10.1042/CS20070261

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  24 in total

1.  Prevalence, types and factors associated with echocardiographic abnormalities among newly diagnosed diabetic patients at Mulago Hospital.

Authors:  Martin Muddu; Edrisa Mutebi; Charles Mondo
Journal:  Afr Health Sci       Date:  2016-03       Impact factor: 0.927

2.  Hypertension and lower walking speed in the elderly: the Three-City study.

Authors:  Julien Dumurgier; Alexis Elbaz; Carole Dufouil; Béatrice Tavernier; Christophe Tzourio
Journal:  J Hypertens       Date:  2010-07       Impact factor: 4.844

3.  Electrocardiographic Left Ventricular Hypertrophy Among Gambian Diabetes Mellitus Patients.

Authors:  M Jobe; A Kane; J C Jones; S Pessinaba; B C Nkum; S Abdou Ba; O A Nyan
Journal:  Ghana Med J       Date:  2015-03

4.  A developmentally regulated spliced variant of PTBP1 is upregulated in type 1 diabetic hearts.

Authors:  KarryAnne Belanger; Curtis A Nutter; Jin Li; Peng Yu; Muge N Kuyumcu-Martinez
Journal:  Biochem Biophys Res Commun       Date:  2018-12-26       Impact factor: 3.575

5.  The CTGF gene -945 G/C polymorphism is not associated with cardiac or kidney complications in subjects with type 2 diabetes.

Authors:  Sheila K Patel; Bryan Wai; Richard J Macisaac; Sharon Grant; Elena Velkoska; Michelle Ord; Sianna Panagiotopoulos; George Jerums; Piyush M Srivastava; Louise M Burrell
Journal:  Cardiovasc Diabetol       Date:  2012-04-26       Impact factor: 9.951

6.  Screening for left ventricular hypertrophy in patients with type 2 diabetes mellitus in the community.

Authors:  Jithendra B Somaratne; Gillian A Whalley; Katrina K Poppe; Mariska M ter Bals; Gina Wadams; Ann Pearl; Warwick Bagg; Rob N Doughty
Journal:  Cardiovasc Diabetol       Date:  2011-04-14       Impact factor: 9.951

7.  NT-proBNP, echocardiographic abnormalities and subclinical coronary artery disease in high risk type 2 diabetic patients.

Authors:  Henrik Reinhard; Peter R Hansen; Niels Wiinberg; Andreas Kjær; Claus L Petersen; Kaj Winther; Hans-Henrik Parving; Peter Rossing; Peter K Jacobsen
Journal:  Cardiovasc Diabetol       Date:  2012-03-05       Impact factor: 9.951

8.  Evidence for a Specific Diabetic Cardiomyopathy: An Observational Retrospective Echocardiographic Study in 656 Asymptomatic Type 2 Diabetic Patients.

Authors:  Isabelle Pham; Emmanuel Cosson; Minh Tuan Nguyen; Isabela Banu; Isabelle Genevois; Patricia Poignard; Paul Valensi
Journal:  Int J Endocrinol       Date:  2015-05-13       Impact factor: 3.257

9.  Brain natriuretic peptide is related to diastolic dysfunction whereas urinary albumin excretion rate is related to left ventricular mass in asymptomatic type 2 diabetes patients.

Authors:  Martin Magnusson; Stefan Jovinge; Kambiz Shahgaldi; Bo Israelsson; Leif Groop; Olle Melander
Journal:  Cardiovasc Diabetol       Date:  2010-01-18       Impact factor: 9.951

10.  Association between intrarenal arterial resistance and diastolic dysfunction in type 2 diabetes.

Authors:  Richard J MacIsaac; Merlin C Thomas; Sianna Panagiotopoulos; Trudy J Smith; Huming Hao; D Geoffrey Matthews; George Jerums; Louise M Burrell; Piyush M Srivastava
Journal:  Cardiovasc Diabetol       Date:  2008-05-23       Impact factor: 9.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.